These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30854694)

  • 21. HIV disease is associated with increased biomarkers of endothelial dysfunction despite viral suppression on long-term antiretroviral therapy in Botswana.
    Mosepele M; Mohammed T; Mupfumi L; Moyo S; Bennett K; Lockman S; Hemphill LC; Triant VA
    Cardiovasc J Afr; 2018 May/Jun 23; 29(3):155-161. PubMed ID: 29771268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.
    Majzoub AM; Nayfeh T; Barnard A; Munaganuru N; Dave S; Singh S; Murad MH; Loomba R
    Aliment Pharmacol Ther; 2021 Oct; 54(7):880-889. PubMed ID: 34435378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial.
    Gawrieh S; Wilson LA; Yates KP; Cummings OW; Vilar-Gomez E; Ajmera V; Kowdley KV; Rosenberg WM; Tonascia J; Chalasani N
    Hepatol Commun; 2021 May; 5(5):786-797. PubMed ID: 34027269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
    Chalasani N; Abdelmalek MF; Loomba R; Kowdley KV; McCullough AJ; Dasarathy S; Neuschwander-Tetri BA; Terrault N; Ferguson B; Shringarpure R; Shapiro D; Sanyal AJ
    Liver Int; 2019 May; 39(5):924-932. PubMed ID: 30253043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
    Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design.
    Zang S; Chen J; Song Y; Bai L; Chen J; Chi X; He F; Sheng H; Wang J; Xie S; Xie W; Yang Y; Zhang J; Zheng M; Zou Z; Wang B; Shi J;
    Adv Ther; 2018 Feb; 35(2):218-231. PubMed ID: 29411270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH).
    Cheng J; Joyce A; Yates K; Aouizerat B; Sanyal AJ
    PLoS One; 2012; 7(9):e44106. PubMed ID: 23028489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are ICAM, VCAM and E-selectin levels different in first manic episode and subsequent remission?
    Turan C; Kesebir S; Süner O
    J Affect Disord; 2014 Jul; 163():76-80. PubMed ID: 24836091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.
    Guy CD; Suzuki A; Abdelmalek MF; Burchette JL; Diehl AM;
    Hepatology; 2015 Jan; 61(1):98-107. PubMed ID: 24849310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes.
    Basu A; Jensen MD; McCann F; Nandy D; Mukhopadhyay D; McConnell JP; Rizza RA
    Endocr Pract; 2007; 13(2):147-52. PubMed ID: 17490928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.
    Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A
    Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
    Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
    Connelly MA; Velez Rivera J; Guyton JR; Siddiqui MS; Sanyal AJ
    Aliment Pharmacol Ther; 2020 Aug; 52(4):619-636. PubMed ID: 32638417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
    Bril F; Kalavalapalli S; Clark VC; Lomonaco R; Soldevila-Pico C; Liu IC; Orsak B; Tio F; Cusi K
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):558-566.e2. PubMed ID: 29223443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of changes in histologic severity of nonalcoholic steatohepatitis and changes in patient-reported quality of life.
    Heath L; Aveyard P; Tomlinson JW; Cobbold JF; Koutoukidis DA
    Hepatol Commun; 2022 Oct; 6(10):2623-2633. PubMed ID: 35903833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
    Ito S; Yukawa T; Uetake S; Yamauchi M
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus.
    Meigs JB; Hu FB; Rifai N; Manson JE
    JAMA; 2004 Apr; 291(16):1978-86. PubMed ID: 15113816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.